Search

for
Search:

Research

5 / 1000+ results

research Development of the CLASI as an outcome instrument for cutaneous lupus erythematosus

52 citations , March 2007 in “Dermatologic Therapy”

This article describes the development and validation of a standardized instrument for measuring skin involvement in cutaneous lupus erythematosus, aiming to aid future clinical research and trials.

research Validation of the Cutaneous Lupus Disease Area and Severity Index (CLASI) using physician- and patient-assessed health outcome measures

40 citations , October 2012 in “Journal of the American Academy of Dermatology”

This study found that the Cutaneous Lupus Disease Area and Severity Index (CLASI) is correlated with both physician-assessed and patient-reported outcomes in cutaneous lupus erythematosus, particularly highlighting concerns about body image in visible areas.

research Clascoterone: First Approval

27 citations , October 2020 in “Drugs”

This article reviews the development milestones of clascoterone up to its first approval for treating acne vulgaris, reporting no new clinical results for androgenetic alopecia.

research Class III Peroxidases PRX01, PRX44, and PRX73 Control Root Hair Growth in Arabidopsis thaliana

19 citations , May 2022 in “International journal of molecular sciences”

This study suggests that PRX01, PRX44, and PRX73 regulate extensin-mediated cell wall properties during root hair cell growth, influencing growth patterns, peroxidase activity, and cell wall thickness.

research Evaluation of disease activity and damage in different subtypes of cutaneous lupus erythematosus using the CLASI

19 citations , September 2010 in “Journal of the European Academy of Dermatology and Venereology”

This study found that while the CLASI is generally useful for assessing disease activity and damage in cutaneous lupus erythematosus, it may not accurately reflect all subtypes, indicating a need for revision.

View more "clays" in research →

Learn

1 / 801 results

learn Clascoterone

a novel topical treatment that inhibits DHT on androgen receptors

Is clascoterone suitable for both men and women? Clascoterone is not approved for hair loss in either sex — the approved product is a 1% acne cream. The scalp version has completed phase III trials in men with sponsor-reported positive results; in women the only data is a company-reported phase II significant in one subgroup, so use is off-label and investigational for both.
What is clascoterone and how does it work against hair loss? Clascoterone is a topical treatment that blocks DHT to prevent hair loss.
How long does it take for clascoterone to show results on hair growth? Clascoterone is not approved for hair loss; it is investigational. In the trials reported so far, application was twice daily and increases in terminal hair count were reported at around 6 months, with more sustained change reported between 6 and 12 months.
All 5 questions on Clascoterone →

View more "clays" in learn →

Community Join

5 / 824 results

community Why isn’t Clascoterone being discussed more?

5 upvotes 3 days ago

Clascoterone is seen as a promising alternative for those who can't tolerate finasteride due to side effects like reduced libido and anxiety. Users discuss using topical finasteride and minoxidil for hair maintenance and consider Clascoterone as a potential future treatment.

community Whatever happened to Clascoterone? (breezula for hair) (sold as Winlevi for acne available since 2021)

4 upvotes 2 weeks ago

Clascoterone (Breezula) is anticipated for release in the coming years but is considered too weak for aggressive androgenetic alopecia (AGA). Current treatments like minoxidil, finasteride, and dutasteride are preferred, with some users obtaining clascoterone from the gray market.

community Clascoterone full results 2026

7 upvotes 2 weeks ago

Clascoterone results are anticipated to be released in fall 2026, possibly at the EADV conference. Users express skepticism and humor about the release date.

community Why is everyone still arguing about PP405 when clascoterone is already heading toward regulatory submission?

46 upvotes 1 month ago

Clascoterone is nearing regulatory submission as a potential new treatment for androgenetic alopecia, with positive Phase III results, while discussions continue about other treatments like PP405, minoxidil, and finasteride. Some users express excitement for clascoterone and Breezula, despite concerns about the effectiveness and practicality of topical treatments.

community Clascoterone might be the Finasteride for female pattern hair loss.

9 upvotes 1 month ago

Clascoterone, a topical anti-androgen, shows promise for treating female pattern hair loss without systemic side effects, offering a potential alternative to minoxidil. It could also benefit men who experience side effects from finasteride.

View more "clays" in community →

Experts

— no results

Try a deeper search in experts →

Clinics

— no results

Try a deeper search in clinics →